Yuntao Cheng1,2 
,
Guangxia Yang3,
Yuansheng Tang1,
Chuanfang Li2,
Meng Zhang2,
Lianqun Cui1
For correspondence:- Yuntao Cheng Email: t1174@163.com
Accepted: 23 December 2018 Published: 31 January 2019
Citation: Cheng Y, Yang G, Tang Y, Li C, Zhang M, Cui L. Effect of recombinant human brain natriuretic peptide on myocardial enzymes and cardiac function after percutaneous coronary intervention in patients with acute myocardial infarction. Trop J Pharm Res 2019; 18(1):123-127 doi: 10.4314/tjpr.v18i1.18
© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To study the effect of recombinant human brain natriuretic peptide rhBNP on myocardial enzymes and cardiac function following percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) subjects.
Methods: Patients with AMI (124 cases) subjected to PCI for 2 years were used as subjects in this investigation. Two groups of patients were used (62 patients per group). One group received rhBNP while the other group served as control. The patients consisted of 76 males and 48 females (mean age, 63.54 ± 12.31 years). The two groups of patients received 75 mg/kg body weight of clopidogrel orally and aspirin (300 mg/kg) 2 h before PCI. The peaks of creatine kinase (CK), creatine kinase MB (CK-MB), and the levels of troponin I (cTnI) were assayed at pre-determined intervals with an automated biochemical analyzer, and changes in the enzyme levels were recorded. Echocardiography (ECG) parameters were also measured.
Results: Lower peaks of CK, CK-MB and levels of cTnI were seen in rhBNP-treated patients, when compared with controls (p < 0.05). Total effectiveness was markedly higher in rhBNP-treated group than in control group (p < 0.05). Moreover, myocardial infarct size was significantly lower in rhBNP treatment group than in control group (p < 0.05).
Conclusion: Treatment with rhBNP before PCI in patients with AMI increases coronary blood flow, ameliorates perfusion injury, inhibits left ventricular remodeling, reduces myocardial cell necrosis, and improves cardiac function and prognosis.
Archives
News Updates
Fulltext in PDF